Live webinar

February 1st | Inter-reader variability can create challenges in oncology trial results. During this 45-minute webinar, Median Technologies will address the 4 main causes of variability occurring during RECIST1.1 assessment and describe control strategies using data analytics and medical investigations. Want to know more? register now!

Register here

Median's latest news

We were very pleased to welcome a large number of participants during our webcast held on October 25th, 2021. Fredrik Brag, CEO and founder of Median presented our company’s latest news and outlook and answered questions from the audience.  You didn’t have the opportunity to join? here is the replay! (in French)

Watch video

Latest press releases

17 January 2022

Median Technologies Announces 2021 Revenue of €20.5 Million, Up 52%, and a Strengthened Cash Position of €39 Million

As of December 31, 2021, Median Technologies’ revenue was €20.5 million, a 52% increase compared to 2020 revenue. The order backlog as of December 31, 2021, was €58 million, a €6.3 million increase compared to December 31, 2020 and a €3,8 million increase compared to September 30, 2021. As of December 31, 2021, cash and cash equivalents were €39 million, compared to €16 million as of December 31, 2020.

5 January 2022

Median Technologies announces outstanding lung nodule detection (CADe) performance for iBiopsy® Lung Cancer Screening

iBiopsy® Lung Cancer Screening detection performance reaches 94.9% sensitivity for a false positive rate of 1 per CT scan, a performance superior to that of lung CADe systems currently on the market. The particularly high sensitivity of iBiopsy® LCS is a prerequisite for implementing a reliable detection and diagnosis solution for lung cancer screening programs. After detection, the diagnostic component of iBiopsy® LCS characterizes nodules as malignant or benign. Its sensitivity/specificity levels were announced in 2021 and are still unparalleled today.

23 November 2021

Median Technologies announces new outstanding performance for its iBiopsy® Lung Cancer Screening CADx with a focus on stage 1 lung cancer characterization

Median Technologies (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules. New results specifically focus on the characterization of stage 1 lung cancer nodules, using Median’s proprietary iBiopsy® deep learning algorithm on low-dose chest computed tomography (LDCT).

21 October 2021

Median Technologies reports on its 2021 half-year results and its Q3 2021 business activity indicators 

Business continues to grow at a sustained pace in the first half of 2021 – Two highly impactful announcements for iBiopsy® and iCRO business units during Q3, 2021 -Third quarter revenue of €5.3m, up by 51% on the third quarter of 2020 – Cash and cash equivalents of €42.6m as of September 30th, 2021

16 September 2021

Median Technologies has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world, and selected to implement their clinical trial imaging strategy on some key oncology indications

This is the result of the renegotiation of terms of an existing Master Service Agreement (MSA) with this major big pharmaceutical company. The new scope of the MSA covers Phase III clinical trials for major indications in oncology and the terms are valid for 3 years. This partnership will contribute to sustain Median’s future bookings and revenues growth.

1/5

Our Autumn Corporate Newsletter

We are pleased to share with you our Autumn Corporate Newsletter, presenting our most recent announcements and what we did during the third quarter of 2021 and in early Q4. Click below to read the Newsletter!

Webinars

February 1, 2022

Discuss the 4 main causes of variability in centralized oncology radiological assessments

Inter-reader variability can create challenges in oncology trial results. During this 45-minute webinar, Median Technologies will address the 4 main causes of variability occurring during RECIST1.1 assessment and describe control strategies using data analytics and medical investigations. Want to know more? Register now!

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more

iBiopsy®

Enhancing imaging diagnostic accuracy

Our team of data scientists, AI engineers and clinicians is focused on developing the most accurate and cutting-edge AI-powered Software as a Medical Device (SaMD). iBiopsy® targets: lung cancer, liver cancer, and NASH to provide to patients an earlier and optimal diagnosis avoiding unnecessary invasive tests.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median